A Bioequivalence Study of Two Formulations of Linagliptin in Healthy Volunteers

The primary objective of this study is to evaluate the bioequivalence of two different formulations of linagliptin. Establishing equivalence ensures that the pharmacokinetic profiles of the formulations are comparable, which is essential for maintaining consistent therapeutic performance in patients. There are no secondary objectives reported.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers, including both male and female individuals. The participants belong to the age group categorized by code 3, which indicates a specific age range. The population includes vulnerable groups.

This bioequivalence clinical trial utilizes a Phase I design to compare two formulations of linagliptin. The study is conducted with healthy volunteers to assess the pharmacokinetic profiles of the tested products. The clinical sequence involves a screening visit to evaluate eligibility, followed by study visits to administer the formulations and collect necessary data. The trial includes follow-up visits and concludes with an end-of-study visit. The total duration of participant involvement is determined by the established protocol, and the trial may be terminated early if predefined safety or efficacy criteria are met.

The assessment of efficacy in this Phase 2 clinical trial involves the evaluation of specific parameters in healthy volunteers. Information regarding the primary and secondary endpoints, measurement methodologies, and the schedule for data collection is not provided.